Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK6 | Q13882 | 1/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.30 |
| ▸ | TTK | P33981 | 2/20 | 0.30 |
| ▸ | CDK1 | P06493 | 1/20 | 0.30 |
| ▸ | CDK2 | P24941 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24112570 | 0.99 | PTK6 (0.33) | PTK6IRAK4TTK | |
| Iodide SCHEMBL25169289 | 0.94 | PTK6 (0.35) | PTK6 | |
| SCHEMBL24112313 | 0.94 | PTK6 (0.35) | PTK6 | |
| SCHEMBL24112575 | 0.94 | PTK6 (0.32) | PTK6IRAK4TTK | |
| SCHEMBL25450764 | 0.93 | PTK6 (0.33) | PTK6TTK | |
| SCHEMBL22123385 | 0.92 | TTK (0.33) | PTK6IRAK4TTKCDK1CDK2 | |
| SCHEMBL30171576 | 0.92 | MAPKAPK5 (0.33) | PTK6IRAK4TTKCDK1CDK2 | |
| SCHEMBL22124583 | 0.92 | MAPKAPK5 (0.33) | PTK6IRAK4TTKCDK1CDK2 | |
| SCHEMBL25450706 | 0.91 | PTK6 (0.35) | PTK6TTK | |
| SCHEMBL22124797 | 0.91 | CDK2 (0.36) | PTK6IRAK4TTKCDK1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4161931-B1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2026-02-18 | — | — | EP | claimed |
| US-20230141600-A1 | IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-05-11 | — | — | US | disclosed |
| EP-4161931-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2023-04-12 | — | — | EP | disclosed |
| CN-115916784-A | Novel imidazopyrazine derivatives | 豪夫迈·罗氏有限公司 | 2023-04-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230141600-A1 | IMIDAZOPYRAZINE DERIVATIVES | IKZF3, RRP15, IK | PTK6 925/4885IRAK4 85/4885TTK 4336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.